Journal
EPIGENOMICS
Volume 12, Issue 6, Pages 543-558Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2019-0275
Keywords
cancer biomarker; liquid biopsy; miRNA; preanalytical variables; prostate cancer
Categories
Funding
- Croatian Science Foundation under Scientific Center of Excellence for Reproductive and Regenerative Medicine, Republic of Croatia [UIP-2017-05-8138]
- European Union through the European Regional Development Fund [KK.01.1.1.01.0008]
- School of Medicine University of Zagreb
Ask authors/readers for more resources
Prostate cancer (PCa) represents the most commonly diagnosed neoplasm among men. miRNAs, as biomarkers, could further improve reliability in distinguishing malignant versus nonmalignant, and aggressive versus nonaggressive PCa. However, conflicting data was reported for certain miRNAs, and there was a lack of consistency and reproducibility, which has been attributed to diverse (pre)analytical factors. In order to address current challenges in miRNA clinical research on PCa, a PubMed-based literature search was conducted with the last update in May 2019. After identifying critical variations in designs and protocols that undermined clear-cut evidence acquisition, and reliable translation into clinical practice, we propose guidelines for most critical steps that should be considered in future research of miRNA as biomarkers, especially in PCa.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available